Introduction
SuperGen is a pharmaceutical company dedicated to the discovery, development and commercialization of therapies to treat patients with cancer. Historically, the company has acquired products that were approved for market or for clinical investigation and applied additional developmental effort to expand sales or advance these products clinically towards potential approval for marketing.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
CLIMB (Computational Lead Identification Modeling Biology) is SuperGen's approach to small molecule drug discovery, which merges rapid screening of compound libraries with computational chemistry and systems biology techniques to identify drug leads that bind to target proteins. Three compounds have been the primary focus of SuperGen's efforts: Dacogen for injection, Orathecin capsules and Nipent (pentostatin for injection). In 2006, Dacogen received approval for marketing in the US, Orathecin was withdrawn from the regulatory review process, Nipent and commercial infrastructure was sold to Mayne Pharma (Hospira). SuperGen's pipeline includes MP470 Tyrosine Kinase Inhibitor/Rad 51 Suppressor and MP529 Aurora A Kinase Inhibitor, which are in preclinical stage of development. SuperGen has derived its revenues from product sales of Nipent and Surface Safe products, royalty from Dacogen sales by MGI Pharma and license fees.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
Report Highlights
[Studien Infos ausblenden]
